VIVIMEDLAB — Vivimed Labs Share Price
Last trade - 00:00- IN₹504.95m
- IN₹4.40bn
- IN₹699.89m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 7.48 | ||
| Price to Sales | 0.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -58.45% | ||
| Return on Equity | n/a | ||
| Operating Margin | -255.02% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 2,372.87 | 1,870.99 | 1,490.71 | 1,162.69 | 699.89 | n/a | n/a | -39.47% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vivimed Labs Limited is an India-based company engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. The Company is primarily engaged in Pharma segment. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. Its manufacturing facilities are equipped to deliver a range of dosage delivery formats that include capsules, tablets, syrups & liquids, sprays & ointments.
Directors
- V. Manohar Rao CHM (75)
- Subhash Varalwar VCH (64)
- Santosh Varalwar MDR (51)
- Sandeep Varalwar EDR (43)
- K. Yugandhar SEC
- Peesapati Venkateswarlu NID (69)
- Last Annual
- March 31st, 2026
- Last Interim
- March 31st, 2026
- Incorporated
- September 22nd, 1988
- Public Since
- August 13th, 2005
- No. of Employees
- 586
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 82,913,915
- Address
- PLOT NO. 78-A, HYDERABAD, 585403
- Web
- https://www.vivimedlabs.com/
- Phone
- +91 4066086608
- Auditors
- SVRL & Co
Latest News for VIVIMEDLAB
Upcoming Events for VIVIMEDLAB
Q1 2027 Vivimed Labs Ltd Earnings Release
Vivimed Labs Ltd Annual Shareholders Meeting
Q2 2027 Vivimed Labs Ltd Earnings Release
Q3 2027 Vivimed Labs Ltd Earnings Release
Similar to VIVIMEDLAB
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 24:04 UTC, shares in Vivimed Labs are trading at IN₹6.09. This share price information is delayed by 15 minutes.
Shares in Vivimed Labs last closed at IN₹6.09 and the price had moved by +23.03% over the past 365 days. In terms of relative price strength the Vivimed Labs share price has outperformed the S&P BSE 100 Index by +38.61% over the past year.
The overall consensus recommendation for Vivimed Labs is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVivimed Labs does not currently pay a dividend.
Vivimed Labs does not currently pay a dividend.
Vivimed Labs does not currently pay a dividend.
To buy shares in Vivimed Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹6.09, shares in Vivimed Labs had a market capitalisation of IN₹504.95m.
Here are the trading details for Vivimed Labs:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: VIVIMEDLAB
Based on an overall assessment of its quality, value and momentum Vivimed Labs is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Vivimed Labs is IN₹134.00. That is 2100.33% above the last closing price of IN₹6.09.
Analysts covering Vivimed Labs currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vivimed Labs. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -3.56%.
As of the last closing price of IN₹6.09, shares in Vivimed Labs were trading -9.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Vivimed Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹6.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Vivimed Labs' management team is headed by:
- V. Manohar Rao - CHM
- Subhash Varalwar - VCH
- Santosh Varalwar - MDR
- Sandeep Varalwar - EDR
- K. Yugandhar - SEC
- Peesapati Venkateswarlu - NID